Tom Piccariello

Dr. Tom Piccariello is a Founder and the President and Chief of Science Officer of Synthonics. Dr. Piccariello was the lead inventor of the Carrierwave technology (attaching a peptide to an active agent to make that agentless subject to abuse) that ultimately led to the discovery, development, and launch of Vyvanse (lisdexamfetamine dimesylate for treatment of ADHD) at New River Pharmaceuticals. Shortly after the commercial launch of Vyvanse, Shire acquired New River for approximately $2.4 billion. Dr. Piccariello has experience in the fields of synthetic chemistry, metallurgy, electrochemistry, plant enzymology, chemical manufacturing, and pharmacology. In addition to serving as the lead scientist for two pharmaceutical start-up companies (both of which became public), Dr. Piccariello founded and ran contract research and contract manufacturing companies, which he later sold. Dr. Piccariello has 23 patents and patent applications to his credit, 18 of which deal with novel drug delivery technologies. He has a B.S. in biology and a Ph.D. in chemistry from Virginia Polytechnic Institute and State University (Virginia Tech).